Bausch + Lomb Affiliate Acquires Whitecap Biosciences

Bausch + Lomb Acquires AcuFocus, Inc.

January 17, 2023

Medical Devices

Bausch + Lomb Corporation has acquired AcuFocus, Inc. through an affiliate via a merger with AcuFocus’s parent company. The acquisition adds AcuFocus’s IC‑8 Apthera small‑aperture extended‑depth‑of‑focus intraocular lens to Bausch + Lomb’s surgical portfolio to expand capabilities in premium cataract IOL offerings.

White Cap Acquires Valley Supply Company

October 3, 2022

Building Products

White Cap L.P. has acquired Valley Supply Company, a Washington-based construction materials supplier with six locations across the state. The acquisition expands White Cap’s Northwest region footprint and adds local branch presence and expertise to serve contractors in the Puget Sound and Central Washington markets.

Bruker Corporation Acquires Canopy Biosciences, LLC

September 11, 2020

Biotechnology

Bruker Corporation has acquired Canopy Biosciences, LLC to strengthen its targeted multi-omics and high-plex biomarker imaging capabilities, adding Canopy's ChipCytometry platform and multi-omics services. Financial terms were not disclosed; Ampersand Capital Partners was identified as Canopy's lead investor.

Optibrium Acquires BioPharmics LLC

August 31, 2023

Software

Optibrium, a Cambridge-based developer of software and AI solutions for small-molecule drug discovery, has acquired BioPharmics LLC to expand its 3D ligand- and structure-based drug design and visualisation capabilities. The acquisition brings BioPharmics' algorithms and products (including ForceGen, Surflex-Dock, eSim and QuanSA) and its founding scientists into Optibrium's StarDrop platform to strengthen 3D modelling, docking and binding-affinity prediction functionality.

Blue Water Ventures International Acquires Psycheceutical, Inc.

January 20, 2022

Biotechnology

Blue Water Ventures International, Inc. (BWVI) has completed a merger to acquire Psycheceutical, Inc., making the biotech a wholly-owned subsidiary. BWVI — a publicly-listed company — will pivot its business to focus on psychedelic drug development and intends to provide near-term capital as Psycheceutical advances its delivery technologies toward initial clinical trials.

Visibly Acquires Lensabl

May 23, 2024

Healthcare Services

Chicago-based digital vision care provider Visibly has acquired Lensabl, a Los Angeles-based tech-enabled optical e-commerce and vision benefits platform. The deal will integrate Lensabl’s direct-to-consumer retail capabilities, white-label shop-in-shop technology and Lensabl+ vision plan offering into Visibly’s telehealth platform to expand its retail and B2B offerings and broaden access to vision care.